This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Congenital Aortic Valve Stenosis대동맥판의 선천성 협착

📋 Contents and key points
ItemDetails
A. Classification codesICD-10: Q23.0 | Special Copayment Reduction: V147 (rare disease)
B. SynonymsCongenital stenosis of aortic valve | Congenital aortic valve atresia | Stenosis
C. Adult onsetLikelihood of first presentation in adulthood low — most are diagnosed from the neonatal period to childhood. However, stenosis based on a mild bicuspid aortic valve may remain asymptomatic until adulthood and be first diagnosed upon discovery of a heart murmur, so first diagnoses in adulthood also occur at a moderate frequency.
1. HistoryBegan with autopsy records; surgical treatment developed after open-heart surgery with cardiopulmonary bypass in 1954; percutaneous balloon valvuloplasty introduced in 1983.
2. CausesEmbryonic fusion of valve commissures is the main cause; bicuspid aortic valve is the most common underlying dysplasia (about 70%).
3. GeneticsAssociated with NOTCH1, GATA5, NKX2.5; multifactorial inheritance or autosomal dominant (incomplete penetrance); familial clustering of BAV.
4. General epidemiologyAbout 1 in 4,000 births; male-to-female ratio about 3–4:1; 3–6% of all congenital heart malformations.
5. PathophysiologyCommissural fusion → reduced effective orifice area → left ventricular pressure overload → concentric hypertrophy → diastolic dysfunction → systolic failure.
6. SymptomsNeonatal shock (severe), heart murmur in childhood, classic adult triad (angina, syncope, heart failure).
7. SignsSystolic ejection murmur (right upper sternal border, 2nd intercostal space), delayed or absent A2 of the second heart sound, systolic thrill, findings of left ventricular hypertrophy.
8. ScreeningNewborn auscultation and pulse oximetry; fetal echocardiography (18–22 weeks of gestation); echocardiographic screening of first-degree relatives of BAV patients.
9. DiagnosisEchocardiography (Doppler pressure gradient and valve area calculation) is the standard; cardiac CT and MRI are complementary; cardiac catheterization is both interventional and diagnostic.
10. TreatmentChildren: BAV as primary intervention; Ross procedure or valve replacement; high-risk adults: TAVI.
11. PrognosisMost can lead normal lives after intervention; long-term follow-up (restenosis, regurgitation, aortic complications) is essential.
12. PreventionPrimary prevention not possible; BAV family screening; endocarditis prevention; regular echocardiographic follow-up after intervention.
13. References10 major clinical guidelines and original papers

1. History

Historical recognition of congenital aortic valve stenosis begins with autopsy descriptions by 18th-century European anatomists. At that time, it was first recorded that a valve fused into a dome shape causes a severe cardiac malformation, and 19th-century clinicians systematically described the distinctive systolic murmur and pulse abnormalities. Until before the 1950s, in most cases only diagnosis was made and effective treatment was impossible.

In 1954, Gibbon succeeded in open-heart surgery using a cardiopulmonary bypass machine, making valve commissurotomy possible, and in 1955 Lillehei, Varco and colleagues performed the first open commissurotomy in a patient with congenital aortic valve stenosis. Thereafter, prosthetic valve replacement was introduced in the 1960s, making complete valve correction possible even in severe patients. In 1967, Donald Ross developed the Ross procedure, transplanting the patient's own pulmonary valve into the aortic position, opening the way to the use of an autologous tissue valve that grows in size with growth, particularly in pediatric patients.

In 1983, Lababidi and colleagues first applied percutaneous balloon aortic valvuloplasty (BAV) to congenital aortic valve stenosis in children, opening the era of nonsurgical intervention. Since then, BAV has become established as the standard primary intervention for congenital aortic valve stenosis in children and adolescents. In 2002, Cribier and colleagues performed the first transcatheter aortic valve implantation (TAVI/TAVR) in high-risk adult patients, providing a new treatment option for adult patients at high surgical risk.

In Korea, surgical correction of congenital heart malformations began in the late 1960s, and with the development of pediatric cardiology and adult congenital cardiology in the 1980s–90s, systematic diagnosis and treatment of congenital aortic valve stenosis became established. Currently, patients registered for Special Copayment Reduction (V147) receive ongoing follow-up at specialist cardiac centers.


2. Causes

Congenital aortic valve stenosis is a disease in which the commissures fail to separate completely during embryonic development of the aortic valve, so that the effective orifice area is congenitally reduced. The normal aortic valve consists of three semilunar cusps—the right coronary cusp, left coronary cusp, and non-coronary cusp—with each commissure fully open. In congenital stenosis, some or all of these commissures are fused.

Bicuspid aortic valve (BAV): about 70–75% of all congenital aortic valve stenosis is based on BAV. BAV is the most common congenital heart malformation, occurring in 1–2% of births, and is a valve consisting of only two leaflets. There may be no stenosis at birth, but stenosis develops over decades as abnormal blood flow damages valve endothelial cells and fibrosis and calcification progress. Unicuspid aortic valve: the rarest but causes the most severe stenosis. Severe stenosis appears from the neonatal period, with blood flow passing through a single orifice. Commissural fusion in a tricuspid valve (fused tricuspid valve): some commissures of a tricuspid valve are fused, forming dome-shaped stenosis.

Genetically, abnormalities in transcription factors such as NOTCH1 (9q34.3), GATA5 (20q13.33), NKX2.5 (5q35.1), and FOXC1/FOXC2 are associated with abnormal valve development, and the frequency of BAV is high in connective tissue disorder syndromes (Turner syndrome, etc.). Embryologically, abnormalities in the migration and remodeling of cardiac neural crest cells and second heart field cells are the key mechanism. Environmental factors such as diabetes, lupus, and rubella infection during pregnancy increase the risk of congenital heart malformations.


3. Genetics

The genetic basis of congenital aortic valve stenosis is dominated by a multifactorial inheritance model rather than single-gene disease. When bicuspid aortic valve (BAV) is the underlying lesion, strong familial clustering is seen.

NOTCH1 gene (9q34.3): Garg et al. (2005, Science) reported that NOTCH1 loss-of-function variants are associated with familial BAV and aortic valve calcification. NOTCH1 plays a key role in the differentiation and maturation of valve endothelial cells and in suppression of abnormal calcification, and abnormalities in the downstream HES/HEY transcription factor pathway cause dysplasia. It is identified in only about 4–10% of all BAV patients.

GATA5 (20q13.33): involved in valve maturation and right coronary artery development; a BAV phenotype is observed in GATA5-deleted mice. NKX2.5 (5q35.1): a transcription factor involved in overall cardiac development; variants are accompanied by atrial septal defects and aortic valve dysplasia. FOXC1, FOXC2: suppress endothelial-to-mesenchymal transition (EndoMT) of valve endothelial cells, and their deletion causes abnormal valve formation.

According to studies of familial clustering of BAV, the frequency of BAV in first-degree relatives is 5–10 times that of the general population. This is explained by multifactorial inheritance or autosomal dominant inheritance (incomplete penetrance). In Turner syndrome (45,X), the frequency of BAV reaches 30–50%. Clinically, echocardiographic screening of first-degree relatives of BAV patients is recommended.


4. General epidemiology

Congenital aortic valve stenosis is relatively common as an isolated anomaly among congenital heart malformations, occurring in about 1 in 4,000 births and accounting for 3–6% of all congenital heart malformations. It should be distinguished from BAV itself (1–2% of births); the frequency of stenosis evident from birth, classified as Q23.0, is lower than this.

Sex distribution: significantly more common in males, with a male-to-female ratio of about 3–4:1. BAV itself is also more common in males. This sex difference is presumed to be partly due to sex-specific regulatory mechanisms of genes such as NOTCH1.

Distribution of severity: critical stenosis in the neonatal period accounts for about 10–15% of the total, and a crisis arises immediately after birth because of ductus-dependent systemic circulation. The remainder are mild to moderate, and stenosis may progress with growth.

Associated malformations: in addition to isolated occurrence, it may also occur as part of the spectrum of coarctation of the aorta (Q25.1), mitral valve abnormalities, ventricular septal defect (VSD), and hypoplastic left heart syndrome (Q23.4).

Situation in Korea: according to statistics from the Health Insurance Review & Assessment Service (HIRA) and rare disease Special Copayment Reduction (V147), congenital aortic and mitral valve malformations in the Q23 code group account for several hundred new diagnoses annually and are an important patient group requiring ongoing follow-up in pediatrics and adult cardiology.


5. Pathophysiology

The core pathophysiology of congenital aortic valve stenosis is pressure overload due to left ventricular outflow tract obstruction (LVOTO).

When the aortic valve commissures fail to separate completely in embryonic life, the effective orifice area (EOA) decreases and the velocity of blood flow through it increases, producing a peak systolic gradient between the left ventricle and aorta. In severe cases, the left ventricle develops concentric hypertrophy to maintain adequate stroke volume; function is initially maintained compensatorily, but in the long term it progresses to diastolic dysfunction and then reduced systolic function (left ventricular failure).

In critical neonatal AS, severe fetal aortic valve stenosis restricts left ventricular growth, and when the ductus arteriosus closes after birth, systemic blood flow decreases abruptly, causing shock. This overlaps with the continuous spectrum of HLHS.

Turbulent flow due to valve stenosis applies abnormal shear stress to valve endothelial cells, promoting fibrosis and calcification. Abnormal pressure waveforms transmitted to the ascending aorta may also cause abnormalities of the aortic media (aortopathy). Because the valve orifice area is fixed relative to the increase in cardiac output during exercise, angina, syncope, and exercise intolerance occur.


6. Symptoms

The clinical symptoms of congenital aortic valve stenosis differ greatly according to the severity of stenosis and the time of presentation.

Neonatal period and infancy (severe): sudden cyanosis, lethargy, feeding difficulty, tachypnea, pallor, and shock appear after closure of the ductus arteriosus. Severe neonatal aortic valve stenosis is an emergency that can be fatal within hours to days. The heart murmur at this age may be surprisingly faint.

Childhood (mild to moderate): many are diagnosed incidentally at health checkups or upon discovery of a heart murmur. Some tire easily or have reduced exercise capacity.

Older children to adults (classic triad): ① angina: chest pain on exertion, due to subendocardial ischemia. ② syncope: syncope during or immediately after exercise, due to reduced peripheral resistance relative to fixed cardiac output or to arrhythmia. ③ heart failure: dyspnea, fatigue, lower-limb edema, nocturnal orthopnea. If even one of these three symptoms occurs, prognosis worsens rapidly, so prompt valve intervention is required.


7. Signs

Auscultation: an ejection systolic murmur at the right upper sternal border, 2nd intercostal space, radiates to the neck. With an underlying bicuspid valve, an ejection click precedes it. The aortic component of the second heart sound (A2) is delayed and diminished, producing paradoxical splitting or a single S2. A fourth heart sound (S4) is commonly heard.

Palpation: the apical impulse is displaced laterally to the left and is sustained (sustained apical impulse). A systolic thrill is palpated at the right upper sternal border, 2nd intercostal space.

Pulse: in moderate or greater stenosis, a slowly rising, low-amplitude pulsus parvus et tardus pattern appears.

ECG: findings of left ventricular hypertrophy (left axis deviation, high voltage in V5–V6, deep S waves in V1–V2, strain pattern ST-T changes). May be normal in mild cases.

Chest X-ray: there may be no cardiomegaly initially, but the cardiac silhouette enlarges with left ventricular failure. Post-stenotic dilatation of the ascending aorta is prominent, especially in BAV.


8. Screening

Universal screening of the general population is not performed, but the following targeted screening is recommended.

Newborn auscultation screening: auscultation for heart murmurs immediately after birth is the primary screening tool. The murmur may be faint in severe stenosis. Pulse oximetry is effective for severe CHD with cyanosis, but sensitivity is low for isolated stenosis because there is no cyanosis.

Fetal echocardiography: performed when a cardiac abnormality is suspected on the standard ultrasound at 18–22 weeks of gestation. Evaluates valve morphology, commissural fusion, left ventricular size and function, and associated malformations. In severe fetal stenosis, in utero balloon valvuloplasty is attempted at selected centers.

Family screening: echocardiographic screening of first-degree relatives (parents, siblings, children) of patients with BAV or congenital aortic valve stenosis is recommended as AHA/ACC Class I.

Management of prenatal risk factors: fetal echocardiography is actively considered in pregnant women with diabetes, lupus, rubella infection, or exposure to teratogenic drugs during pregnancy.


9. Diagnosis

Echocardiography: the gold standard for diagnosis. Two-dimensional transthoracic echocardiography (2D-TTE) evaluates valve morphology, commissural fusion, thickness, and calcification, and Doppler quantifies peak and mean pressure gradients, effective orifice area (continuity equation), and left ventricular function. Severe criteria: peak velocity ≥4 m/s, mean gradient ≥40 mmHg, valve area ≤1.0 cm² (or ≤0.6 cm²/m² BSA). Transesophageal echocardiography (TEE) is used for detailed evaluation of valve anatomy.

ECG and chest X-ray: indirect evidence of left ventricular hypertrophy; useful for follow-up.

Cardiac CT angiography: used to quantify valve calcification (Agatston score), evaluate aortic anatomy, and plan surgery and intervention. In children, used selectively in consideration of radiation exposure.

Cardiac MRI: detailed evaluation of left ventricular volume, mass, and function, and assessment of myocardial fibrosis. Useful in patients with a poor echocardiographic window.

Cardiac catheterization: performed when noninvasive tests are insufficient or for therapeutic intervention (BAV). Direct measurement of the pressure gradient and calculation of cardiac output and valve area (Gorlin formula).


10. Treatment

Indications for intervention: ① severe stenosis + symptoms (angina, syncope, heart failure) or EF <50% ② even if asymptomatic and severe, reduced left ventricular systolic function, excessive hypertrophy, or abnormal exercise test ③ critical neonatal stenosis — immediate intervention required.

Percutaneous balloon aortic valvuloplasty (BAV): primary intervention in children and adolescents. Immediate reduction in pressure gradient, success rate 85–90%. Restenosis requires long-term reintervention. In adults, limited use as a bridge before surgery or in pregnant women and high-risk patients.

Ross procedure: transplantation of the patient's own pulmonary valve into the aortic position. Advantages in children of growth potential and no need for anticoagulation. Issues include neoaortic dilation and durability of the autologous pulmonary valve.

Surgical valve repair and replacement: commissurotomy, valve repair, or valve replacement (mechanical/bioprosthetic) is chosen according to valve structure. Mechanical valves: excellent durability, lifelong anticoagulation required. Bioprosthetic valves: no anticoagulation required; reoperation may be needed due to degeneration after 10–15 years.

TAVI/TAVR: currently applied to adults at high risk or inoperable; pediatric application is at the research stage.


11. Prognosis

Critical neonatal stenosis: currently, survival exceeds 90% after immediate BAV or surgical correction at specialist centers. Intensive follow-up is needed because of the possibility of long-term restenosis, regurgitation, and progression to HLHS.

Long-term course after BAV: within 5–10 years, about 30–50% require reintervention because of restenosis or progression of regurgitation. 20-year survival is 85–90%, but the proportion living without reoperation is 40–50%.

After the Ross procedure: in adults, 15–20-year freedom from reoperation is about 70–75%. Neoaortic dilation and degeneration of the pulmonary homograft are the main long-term challenges.

BAV aortopathy: ascending aortic dilation accompanies 50–70% of BAV patients. The risk of aortic dissection is 5–8 times that of the general population. Prophylactic surgery is considered if the aortic diameter is 45 mm or more (40 mm with risk factors).

Infective endocarditis: a dysplastic aortic valve is a site at risk for endocarditis. In high-risk patients, prophylactic antibiotics before invasive procedures are considered.


12. Prevention

Primary prevention (preventing occurrence) of congenital aortic valve stenosis itself is currently not possible.

Avoiding risk factors during pregnancy: rubella prevention (MMR vaccine), abstaining from alcohol and smoking, avoiding teratogenic drugs, and folic acid supplementation can lower the overall risk of congenital heart malformations.

Family screening: echocardiographic screening of first-degree relatives of patients with BAV or congenital aortic valve stenosis is recommended as Class I in the AHA/ACC guidelines. Early diagnosis enables planned treatment.

Prevention of infective endocarditis: in high-risk patients (after valve replacement, history of endocarditis), prophylactic amoxicillin 2 g orally (or ampicillin 2 g IV) before invasive oral procedures.

Exercise and activity restrictions: in severe stenosis, high-intensity competitive sports and strenuous isometric exercise are restricted. Mild to moderate cases require individual assessment. Pre-pregnancy cardiology evaluation and specialized prenatal care are essential.

Regular follow-up echocardiography: mild: every 3–5 years; moderate: every 1–2 years; severe: every 6–12 months. In BAV patients, changes in aortic diameter are also monitored.


13. References

  1. Siu SC, Silversides CK. Bicuspid aortic valve disease. J Am Coll Cardiol. 2010;55(25):2789-2800. DOI: 10.1016/j.jacc.2009.12.068. PMID: 20579530.

  2. Garg V, Muth AN, Ransom JF, et al. Mutations in NOTCH1 cause aortic valve disease. Nature. 2005;437(7056):270-274. DOI: 10.1038/nature03940. PMID: 16025100.

  3. Otto CM, Nishimura RA, Bonow RO, et al. 2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease. J Am Coll Cardiol. 2021;77(4):e25-e197. DOI: 10.1016/j.jacc.2020.11.018. PMID: 33342586.

  4. Baumgartner H, De Backer J, Babu-Narayan SV, et al. 2020 ESC Guidelines for the management of adult congenital heart disease. Eur Heart J. 2021;42(6):563-645. DOI: 10.1093/eurheartj/ehaa554. PMID: 32860028.

  5. Warnes CA, Williams RG, Bashore TM, et al. ACC/AHA 2008 Guidelines for the Management of Adults with Congenital Heart Disease. J Am Coll Cardiol. 2008;52(23):e143-e263. DOI: 10.1016/j.jacc.2008.10.001. PMID: 19038677.

  6. Brown JW, Rodefeld MD, Ruzmetov M, et al. Surgical valvuloplasty versus balloon aortic dilation for congenital aortic stenosis. Ann Thorac Surg. 2012;94(1):146-155. DOI: 10.1016/j.athoracsurg.2012.03.001. PMID: 22503272.

  7. Hoffman JI, Kaplan S. The incidence of congenital heart disease. J Am Coll Cardiol. 2002;39(12):1890-1900. DOI: 10.1016/S0735-1097(02)01886-7. PMID: 12084585.

  8. Niwa K, Perloff JK, Bhuta SM, et al. Structural abnormalities of great arterial walls in congenital heart disease. Circulation. 2001;103(3):393-400. DOI: 10.1161/01.CIR.103.3.393. PMID: 11157694.

  9. Hiratzka LF, Bakris GL, Beckman JA, et al. 2010 ACCF/AHA/AATS Guidelines for Thoracic Aortic Disease. Circulation. 2010;121(13):e266-e369. DOI: 10.1161/CIR.0b013e3181d4739e. PMID: 20233780.

  10. Egbe AC, Poterucha JT, Brinjikji W, et al. Outcomes in adults with congenital aortic stenosis undergoing aortic valve replacement. Heart. 2016;102(19):1561-1567. DOI: 10.1136/heartjnl-2016-309471. PMID: 27188380.